FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 378 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Risk of Distant Recurrence of ER-Positive Breast Cancer in Premenopausal Women... May 8, 2021 FDA Approvals Expand Initial Treatment Options for Multiple Myeloma January 7, 2025 Shannon’s Law Requires NY Insurance Companies to Cover Mammograms for Ages... August 9, 2019 Trastuzumab Deruxtecan Demonstrates Efficacy in HER2-positive and HER2-low Advanced Gastric Cancer July 6, 2021 Load more HOT NEWS Could A Diabetes Diagnosis Help Detect Pancreatic Cancer Early? Saving Time for Patients and Improving Well-Being Through Mindfulness and Fitness:... EMA Recommends Granting a Marketing Authorisation for Fedratinib FDA Approves Pembrolizumab for Advanced MSI-H/dMMR Endometrial Carcinoma
